Clinical Trial Detail
| NCT ID | NCT04082364 |
| Title | Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | MacroGenics |
| Indications | |
| Therapies |
Fluorouracil + Leucovorin + Margetuximab + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Capecitabine + Margetuximab + Oxaliplatin + Retifanlimab Capecitabine + Margetuximab + MGD013 + Oxaliplatin Capecitabine + Oxaliplatin + Trastuzumab Fluorouracil + Leucovorin + Margetuximab + Oxaliplatin + Retifanlimab Capecitabine + Margetuximab + Oxaliplatin Fluorouracil + Leucovorin + Margetuximab + MGD013 + Oxaliplatin |
| Age Groups: | senior adult |
CKB BOOST